Outlook Therapeutics (NASDAQ:OTLK) versus Candel Therapeutics (NASDAQ:CADL) Financial Survey

Candel Therapeutics (NASDAQ:CADL) and Outlook Therapeutics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Institutional & Insider Ownership

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 11.2% of Outlook Therapeutics shares are owned by institutional investors. 41.6% of Candel Therapeutics shares are owned by insiders. Comparatively, 3.4% of Outlook Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings for Candel Therapeutics and Outlook Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	0	0	1	0	3.00
Outlook Therapeutics	0	1	6	0	2.86

Candel Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 106.07%. Outlook Therapeutics has a consensus price target of $32.73, indicating a potential upside of 1,361.31%. Given Outlook Therapeutics’ higher possible upside, analysts plainly believe Outlook Therapeutics is more favorable than Candel Therapeutics.

Valuation & Earnings

This table compares Candel Therapeutics and Outlook Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	$120,000.00	2,495.24	-$37.94 million	($1.73)	-5.33
Outlook Therapeutics	N/A	N/A	-$58.98 million	($8.94)	-0.25

Candel Therapeutics has higher revenue and earnings than Outlook Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Outlook Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Candel Therapeutics has a beta of -0.95, suggesting that its stock price is 195% less volatile than the S&P 500. Comparatively, Outlook Therapeutics has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Profitability

This table compares Candel Therapeutics and Outlook Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-629.29%	-173.39%
Outlook Therapeutics	N/A	N/A	-160.88%

About Candel Therapeutics

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

About Outlook Therapeutics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.